Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Nektar to cut over 500 jobs following cancer drug failure

Published 04/25/2022, 07:59 PM
Updated 04/25/2022, 08:00 PM
©  Reuters

© Reuters

(Reuters) - Nektar Therapeutics (NASDAQ:NKTR) said on Monday it would lay off about 70% of its workforce, or more than 500 employees, after stopping the development of its key cancer drug earlier in the month.

The company scrapped all clinical trials of the drug, bempegaldesleukin, including those in combination with Bristol Myers (NYSE:BMY) Squibb Co's cancer drug Opdivo, after the therapy failed to meet the main goal in several studies.

The layoffs are expected to result in a charge of between $150 million and $160 million, most of which would be recorded in the second quarter, Nektar said. Its chief medical officer and chief commerical officer would also step down.

Shares of the company were 3% lower in extended trading.

Nektar said the restructuring would help ensure that it has enough capital to fund the development of drugs that it considers "most impactful" to its future.

These include NKTR-358, an experimental treatment for autoimmune and inflammatory diseases that is being developed in partnership with Eli Lilly (NYSE:LLY), and NKTR-255, which is being studied in clinical trials in patients with head and neck and colorectal cancer.

The company expects to end the year with about $440 million to $450 million in cash and investments and no debt.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.